5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.95▼ | 1.94▲ | 1.92▲ | 1.78▲ | 1.56▲ |
MA10 | 1.95▼ | 1.90▲ | 1.87▲ | 1.68▲ | 1.33▲ |
MA20 | 1.94▲ | 1.85▲ | 1.83▲ | 1.51▲ | 1.01▲ |
MA50 | 1.87▲ | 1.76▲ | 1.70▲ | 1.24▲ | 0.77▲ |
MA100 | 1.80▲ | 1.67▲ | 1.56▲ | 0.94▲ | 1.01▲ |
MA200 | 1.70▲ | 1.51▲ | 1.40▲ | 0.77▲ | 8.33▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.005▼ | 0.008▲ | 0.009▲ | 0.030▲ | 0.107▲ |
RSI | 63.333▲ | 76.211▲ | 75.067▲ | 68.613▲ | 75.261▲ |
STOCH | 27.500 | 92.386▲ | 91.803▲ | 80.322▲ | 73.566 |
WILL %R | -66.667 | -10.256▲ | -9.091▲ | -2.985▲ | -1.476▲ |
CCI | -83.912 | 97.778 | 117.195▲ | 158.035▲ | 157.760▲ |
Friday, June 06, 2025 05:44 AM
Under ABVC's existing licensing framework with OncoX, a share of these revenues will flow back to ABVC in the form of royalty payments, allowing ABVC to capitalize on downstream value. This ...
|
Tuesday, June 03, 2025 03:12 AM
Silicon Valley, CA - (NewMediaWire) - June 03, 2025 - - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing ...
|
Wednesday, May 14, 2025 06:15 AM
SILICON VALLEY, CA - May 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 1.805 | 1.965 | 1.79 | 1.945 | 480,023 |
13/06/25 | 1.80 | 1.85 | 1.74 | 1.77 | 284,842 |
12/06/25 | 1.67 | 1.85 | 1.58 | 1.85 | 362,574 |
11/06/25 | 1.64 | 1.695 | 1.6008 | 1.67 | 83,406 |
10/06/25 | 1.65 | 1.67 | 1.60 | 1.67 | 228,368 |
09/06/25 | 1.59 | 1.6499 | 1.5493 | 1.62 | 298,634 |
06/06/25 | 1.55 | 1.65 | 1.4801 | 1.54 | 374,542 |
05/06/25 | 1.57 | 1.61 | 1.42 | 1.50 | 349,242 |
04/06/25 | 1.69 | 1.73 | 1.55 | 1.58 | 313,588 |
03/06/25 | 1.62 | 1.81 | 1.62 | 1.65 | 532,312 |
|
|
||||
|
|
||||
|
|